Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:GSK
|
| gptkbp:acquisitionYear |
2022
|
| gptkbp:CEO |
gptkb:Ankit_Mahadevia
|
| gptkbp:focusesOn |
infectious diseases
antibiotic development |
| gptkbp:foundedYear |
2013
|
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Spero Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:Tebipenem_HBr
|
| gptkbp:numberOfEmployees |
approximately 50 (as of 2022)
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:researchArea |
multi-drug resistant bacterial infections
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:SPRO
|
| gptkbp:type |
gptkb:public_company
|
| gptkbp:website |
https://sperotherapeutics.com/
|
| gptkbp:bfsParent |
gptkb:Atlas_Venture
|
| gptkbp:bfsLayer |
6
|